Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

In other domains, selected coagulation and platelet traits showed probable-robust signals, vitamin D evidence was insufficient, and gut microbiota instruments provided preliminary robust evidence for Bacilli and Family XIII AD3011 association with RVO.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Systematic review.

Systematic review

Uses explicit methods to identify, assess and summarise research on a defined question.

Meta-analysis not reported · Blinding not applicable to this review · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Unraveling causal pathways in retinal vein occlusion: a systematic review of Mendelian randomization studies

Source: Article title.

Because no universally accepted meta-analysis tool exists for MR bias, this checklist served as our primary standard.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Unraveling causal pathways in retinal vein occlusion: a systematic review of Mendelian randomization studies

Systematic review · International Journal of Retina and Vitreous · 2025

Original publication title

Unraveling causal pathways in retinal vein occlusion: a systematic review of Mendelian randomization studies

Anas Alamoudi; Ahmed Alnabihi; Sultan Al-Qahtani; Abdulaziz Aiyidh S. Aljiayyd; Waleed K. Alsarhani; Suzan Y. Alharbi; Andrew Mihalache; Marko Popovic; Rajeev H. Muni; Adel G. Alakeely

© The Author(s) 2025

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Genetic evidence supports a multifactorial vascular-metabolic model for RVO in which elevated IOP, glaucoma, hypertension, adiposity, and acute hyperglycemia are genetically supported risk factors. These findings highlight blood-pressure control, weight management, and glycemic regulation as important prevention targets and underscore the need for ancestry-diverse MR studies with refined phenotyping.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Retinal vein occlusion (RVO) is a leading cause of vision loss, yet there are inconsistent risk estimates related to risk factors. Mendelian randomization (MR) uses genetic variants as proxies for lifelong exposure and can clarify causal pathways for RVO. We aimed to systematically review MR studies to identify causally supported systemic and ocular risk factors for RVO.

Source: Background

Abstract: What methods does the paper describe?

Four databases (PubMed, Embase, Scopus, and Web of Science) were searched from inception to June 2025 for peer-reviewed MR studies evaluating modifiable systemic or ocular risk factors in relation to any form of RVO utilizing GWAS data. Narrative synthesis was undertaken as methodological heterogeneity precluded meta-analysis. All effect estimates (ORs) were extracted directly from individual studies and robustness of evidence for each exposure across studies was assessed as robust, probable, suggestive, insufficient, and non-evaluable based on significance and direction of evidence.

Source: Methods

Abstract: Results

Twelve two-sample MR studies, all conducted in European cohorts, met inclusion criteria. Ocular traits showed the most consistent signals: higher intraocular pressure (RVO (OR = 1.53, 95% CI: 1.0402.26) and glaucoma liability (OR = 1.31, 95% CI: 1.18 to 1.45) were robustly associated with greater risk of RVO. Among cardiovascular factors, elevated blood pressure/hypertension liability demonstrated probable evidence of increased RVO risk (OR = 1.58, 95% CI: 1.34 to 1.85), whereas lipid profiles yielded mixed signals, with some support for higher LDL (OR = 1.23, 95% CI: 1.05 to 1.44) and total cholesterol (OR = 1.44, 95% CI: 1.08 to 1.92) effects.

For metabolic factors, glycemic traits showed probable to robust evidence with fasting glucose (OR = 5.01, 95% CI: 2.00-12.55) and two-hour glucose (OR = 3.17, 95% CI: 1.63 to 6.18) associated with higher RVO risk. Similarly, type 2 diabetes liability showed probable evidence (OR = 2.82, 95% CI: 2.07 to 3.85); anthropometric measures offered probable to robust support with body mass index (OR = 1.94, 95% CI: 1.23 to 3.08) and waist circumference (OR = 2.40, 95% CI: 1.36 to 4.24) associated with RVO. In other domains, selected coagulation and platelet traits showed probable-robust signals, vitamin D evidence was insufficient, and gut microbiota instruments provided preliminary robust evidence for Bacilli and Family XIII AD3011 association with RVO.

Source: Results

Abstract: Conclusion

Genetic evidence supports a multifactorial vascular-metabolic model for RVO in which elevated IOP, glaucoma, hypertension, adiposity, and acute hyperglycemia are genetically supported risk factors. These findings highlight blood-pressure control, weight management, and glycemic regulation as important prevention targets and underscore the need for ancestry-diverse MR studies with refined phenotyping.

Source: Conclusion
Authors’ abstract

Background

Retinal vein occlusion (RVO) is a leading cause of vision loss, yet there are inconsistent risk estimates related to risk factors. Mendelian randomization (MR) uses genetic variants as proxies for lifelong exposure and can clarify causal pathways for RVO. We aimed to systematically review MR studies to identify causally supported systemic and ocular risk factors for RVO.

Methods

Four databases (PubMed, Embase, Scopus, and Web of Science) were searched from inception to June 2025 for peer-reviewed MR studies evaluating modifiable systemic or ocular risk factors in relation to any form of RVO utilizing GWAS data. Narrative synthesis was undertaken as methodological heterogeneity precluded meta-analysis. All effect estimates (ORs) were extracted directly from individual studies and robustness of evidence for each exposure across studies was assessed as robust, probable, suggestive, insufficient, and non-evaluable based on significance and direction of evidence.

Results

Twelve two-sample MR studies, all conducted in European cohorts, met inclusion criteria. Ocular traits showed the most consistent signals: higher intraocular pressure (RVO (OR = 1.53, 95% CI: 1.0402.26) and glaucoma liability (OR = 1.31, 95% CI: 1.18 to 1.45) were robustly associated with greater risk of RVO. Among cardiovascular factors, elevated blood pressure/hypertension liability demonstrated probable evidence of increased RVO risk (OR = 1.58, 95% CI: 1.34 to 1.85), whereas lipid profiles yielded mixed signals, with some support for higher LDL (OR = 1.23, 95% CI: 1.05 to 1.44) and total cholesterol (OR = 1.44, 95% CI: 1.08 to 1.92) effects.

For metabolic factors, glycemic traits showed probable to robust evidence with fasting glucose (OR = 5.01, 95% CI: 2.00-12.55) and two-hour glucose (OR = 3.17, 95% CI: 1.63 to 6.18) associated with higher RVO risk. Similarly, type 2 diabetes liability showed probable evidence (OR = 2.82, 95% CI: 2.07 to 3.85); anthropometric measures offered probable to robust support with body mass index (OR = 1.94, 95% CI: 1.23 to 3.08) and waist circumference (OR = 2.40, 95% CI: 1.36 to 4.24) associated with RVO. In other domains, selected coagulation and platelet traits showed probable-robust signals, vitamin D evidence was insufficient, and gut microbiota instruments provided preliminary robust evidence for Bacilli and Family XIII AD3011 association with RVO.

Conclusion

Genetic evidence supports a multifactorial vascular-metabolic model for RVO in which elevated IOP, glaucoma, hypertension, adiposity, and acute hyperglycemia are genetically supported risk factors. These findings highlight blood-pressure control, weight management, and glycemic regulation as important prevention targets and underscore the need for ancestry-diverse MR studies with refined phenotyping.

Supplementary Information

The online version contains supplementary material available at 10.1186/s40942-025-00753-7.

Publication and source details

Original title: Unraveling causal pathways in retinal vein occlusion: a systematic review of Mendelian randomization studies

Anas Alamoudi; Ahmed Alnabihi; Sultan Al-Qahtani; Abdulaziz Aiyidh S. Aljiayyd; Waleed K. Alsarhani; Suzan Y. Alharbi; Andrew Mihalache; Marko Popovic; Rajeev H. Muni; Adel G. Alakeely

International Journal of Retina and Vitreous · 2025

© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T00:40:47.744931+00:00

DOI: 10.1186/s40942-025-00753-7 · PMC12676853